Compare FTK & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTK | CTNM |
|---|---|---|
| Founded | 1985 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 522.1M | 575.3M |
| IPO Year | 1997 | 2024 |
| Metric | FTK | CTNM |
|---|---|---|
| Price | $16.57 | $15.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $20.00 | $18.60 |
| AVG Volume (30 Days) | ★ 232.9K | 224.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 440.00 | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $136,092,000.00 | N/A |
| Revenue This Year | $20.30 | N/A |
| Revenue Next Year | $11.14 | N/A |
| P/E Ratio | $22.29 | ★ N/A |
| Revenue Growth | ★ 214.53 | N/A |
| 52 Week Low | $6.05 | $3.35 |
| 52 Week High | $20.09 | $16.01 |
| Indicator | FTK | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 49.32 | 63.90 |
| Support Level | $16.88 | $14.30 |
| Resistance Level | $17.98 | $16.00 |
| Average True Range (ATR) | 1.04 | 1.02 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 49.71 | 85.35 |
Flotek Industries Inc is a technology-driven specialty chemistry and data company. It has two reportable segments: Its Chemistry Technologies segment includes specialty chemistries, logistics and technology services. It also include integrated oil and gas companies, oilfield services companies, independent oil and gas companies, national and state-owned oil companies, and international supply chain management companies. The Data Analytics segment provides analytical measurement solutions and deliver real-time information and insights to customers to enable optimization of operations and reduction of emissions and their carbon intensity. Key revenue comes from its Chemistry Technologies segment.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.